Adrenomyeloneuropathy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ADR022 MIFTS: 39	Adrenomyeloneuropathy Categories: Rare diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Adrenomyeloneuropathy

MalaCards integrated aliases for Adrenomyeloneuropathy:

Name: Adrenomyeloneuropathy ⁵³ ⁷³

Adrenoleukodystrophy ⁷³

Amn ⁵³

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

UMLS ⁷³ C1527231

Sources

Summaries for Adrenomyeloneuropathy

NIH Rare Diseases : ⁵³ Adrenomyeloneuropathy (AMN) is an inherited condition that affects the spinal cord. It is a form of X-linked adrenoleukodystrophy. On average, people with AMN begin to develop features in the late twenties. Signs and symptoms may include progressive stiffness and weakness of the legs; ataxia; speech difficulties; adrenal insufficiency; sexual dysfunction; and bladder control issues. Some people with AMN also have brain involvement which can lead to behavioral abnormalities, vision loss, hearing problems, and/or seizures. AMN is caused by changes (mutations) in the ABCD1 gene and is inherited in an X-linked manner. Treatment addresses the symptoms in each person and may include steroid replacement therapy for adrenal insufficiency.

MalaCards based summary : Adrenomyeloneuropathy, also known as adrenoleukodystrophy, is related to adrenoleukodystrophy and megaloblastic anemia 1, and has symptoms including ataxia, muscle spasticity and seizures. An important gene associated with Adrenomyeloneuropathy is ABCD1 (ATP Binding Cassette Subfamily D Member 1), and among its related pathways/superpathways are G alpha (s) signalling events and Peroxisome. The drugs Cyclophosphamide and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone.

Wikipedia : ⁷⁶ Adrenoleukodystrophy is a disease linked to the X chromosome. It is a result of fatty acid buildup... more...

Sources

Related Diseases for Adrenomyeloneuropathy

Diseases related to Adrenomyeloneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)

#	Related Disease	Score	Top Affiliating Genes
1	adrenoleukodystrophy	12.0
2	megaloblastic anemia 1	12.0
3	childhood-onset cerebral x-linked adrenoleukodystrophy	10.9
4	spasticity	10.2
5	spastic paraparesis	10.1
6	cerebritis	10.1
7	neuropathy	9.9
8	aging	9.8
9	thrombocytopenia	9.8
10	spastic ataxia	9.8
11	autonomic neuropathy	9.8
12	polyneuropathy	9.8
13	hypothyroidism	9.8
14	spondylosis	9.8
15	cervicitis	9.8
16	pituitary gland disease	9.8
17	paraplegia	9.8
18	neuronitis	9.8
19	cerebral degeneration	9.1	ABCD1 SLC25A17

Graphical network of the top 20 diseases related to Adrenomyeloneuropathy:

Sources

Symptoms & Phenotypes for Adrenomyeloneuropathy

UMLS symptoms related to Adrenomyeloneuropathy:

ataxia, muscle spasticity, seizures, paraparesis, absence of sensation, unspecified visual loss

Sources

Drugs & Therapeutics for Adrenomyeloneuropathy

Drugs for Adrenomyeloneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cyclophosphamide

Approved, Investigational

Phase 2, Phase 3,Phase 3

50-18-0, 6055-19-2

2907

Busulfan

Approved, Investigational

Phase 2, Phase 3,Phase 3

55-98-1

2478

Prednisolone

Approved, Vet_approved

Phase 2, Phase 3

50-24-8

5755

Methylprednisolone

Approved, Vet_approved

Phase 2, Phase 3

83-43-2

6741

Glycerol

Approved, Investigational

Phase 2, Phase 3

56-81-5

753

Betaine

Approved, Nutraceutical

Phase 3

107-43-7

247

Biotin

Approved, Investigational, Nutraceutical

Phase 2, Phase 3

58-85-5

171548

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

59-30-3

6037

Prednisolone acetate

Phase 2, Phase 3

Alkylating Agents

Phase 2, Phase 3,Not Applicable

Methylprednisolone acetate

Phase 2, Phase 3

Methylprednisolone Hemisuccinate

Phase 2, Phase 3

Micronutrients

Phase 2, Phase 3,Phase 1

Cholic Acids

Phase 3,Not Applicable

Gastrointestinal Agents

Phase 3,Not Applicable

Trace Elements

Phase 2, Phase 3,Phase 1

Vitamin B Complex

Phase 2, Phase 3

Hypolipidemic Agents

Phase 3,Not Applicable

Vitamins

Phase 2, Phase 3,Phase 1

Immunosuppressive Agents

Phase 2, Phase 3,Not Applicable

Prednisolone hemisuccinate

Phase 2, Phase 3

Prednisolone phosphate

Phase 2, Phase 3

Liver Extracts

Phase 3

Lipid Regulating Agents

Phase 3,Not Applicable

Antilymphocyte Serum

Phase 2, Phase 3

Antirheumatic Agents

Phase 2, Phase 3,Not Applicable

Antimetabolites

Phase 3,Phase 2,Not Applicable

Bile Acids and Salts

Phase 3,Not Applicable

Antineoplastic Agents, Alkylating

Phase 2, Phase 3,Not Applicable

Pharmaceutical Solutions

Phase 2, Phase 3

Folate

Nutraceutical

Phase 2, Phase 3

Vitamin B7

Nutraceutical

Phase 2, Phase 3

Vitamin B9

Nutraceutical

Phase 2, Phase 3

alemtuzumab

Approved, Investigational

Phase 2,Not Applicable

216503-57-0

Hydroxyurea

Approved

Phase 2

127-07-1

3657

Mesna

Approved, Investigational

Phase 2

3375-50-6

598

Clofarabine

Approved, Investigational

Phase 2,Not Applicable

123318-82-1

119182

Miconazole

Approved, Investigational, Vet_approved

Phase 2,Not Applicable

22916-47-8

4189

Melphalan

Approved

Phase 2,Not Applicable

148-82-3

4053 460612

Mycophenolic acid

Approved

Phase 2,Not Applicable

24280-93-1

446541

Benzocaine

Approved, Investigational

Phase 2,Not Applicable

1994-09-7, 94-09-7

2337

Mycophenolate mofetil

Approved, Investigational

Phase 2,Not Applicable

128794-94-5

5281078

Acetylcysteine

Approved, Investigational

Phase 2

616-91-1

12035

rituximab

Approved

Phase 2

174722-31-7

10201696

Fludarabine

Approved

Phase 2

21679-14-1, 75607-67-9

30751

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Tocopherol

Approved, Investigational, Nutraceutical

Phase 2

1406-66-2

14986

tannic acid

Approved, Nutraceutical

Phase 2,Not Applicable

Vitamin E

Approved, Nutraceutical, Vet_approved

Phase 2

59-02-9

14985

Interventional clinical trials:

(show all 40)

#	Name	Status	NCT ID	Phase	Drugs
1	MD1003-AMN MD1003 in Adrenomyeloneuropathy	Completed	NCT02961803	Phase 2, Phase 3	MD1003 100 mg capsule;Placebo
2	Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid	Completed	NCT00007020	Phase 3	Cholic Acids
3	Stem Cell Transplant for Inborn Errors of Metabolism	Completed	NCT00176904	Phase 2, Phase 3	Busulfan, Cyclophosphamide, Antithymocyte Globulin
4	Betaine and Peroxisome Biogenesis Disorders	Completed	NCT01838941	Phase 3	Betaine
5	A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.	Recruiting	NCT03231878	Phase 2, Phase 3	MIN-102;Placebos
6	A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)	Active, not recruiting	NCT01896102	Phase 2, Phase 3
7	Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy	Suspended	NCT00004418	Phase 2, Phase 3	glyceryl trierucate;glyceryl trioleate
8	A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy	Terminated	NCT00545597	Phase 3	Lorenzo's oil
9	ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases	Terminated	NCT00654433	Phase 3
10	A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants	Completed	NCT01495260	Phase 2	N-acetylcysteine;lipoic acid;vitamin E
11	HSCT for High Risk Inherited Inborn Errors	Completed	NCT00383448	Phase 2	Clofarabine;Melphalan;Alemtuzumab;mycophenylate mofetil;Hydroxyurea
12	Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders	Completed	NCT01043640	Phase 2	Campath-1H;Cyclophosphamide;Busulfan;Cyclosporine A;Mycophenolate Mofetil
13	Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy	Recruiting	NCT03196765	Phase 1, Phase 2	Sobetirome (NV1205)
14	A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy	Recruiting	NCT02595489	Phase 1, Phase 2
15	Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy	Recruiting	NCT02559830	Phase 1, Phase 2
16	MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis	Recruiting	NCT02171104	Phase 2	IMD Preparative Regimen;Osteopetrosis Only Preparative Regimen;Osteopetrosis Haploidentical Only Preparative Regimen;cALD SR-A (Standard-Risk, Regimen A);cALD SR-B (Standard-Risk, Regimen B);cALD HR-D (High-Risk, Regimen C);cALD HR-D (High-Risk, Regimen D)
17	Busulfan, Fludarabine, and Thiotepa Conditioning Regimen for Non Malignant Disease	Recruiting	NCT03513328	Phase 1, Phase 2	Thiotepa--single daily dose;Thiotepa--escalated dose
18	MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)	Recruiting	NCT03406962	Phase 2	MGTA-456
19	Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT	Recruiting	NCT01962415	Phase 2	Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa
20	Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders	Active, not recruiting	NCT01372228	Phase 1, Phase 2
21	Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases	Not yet recruiting	NCT03367546	Phase 2
22	UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells	Recruiting	NCT02254863	Phase 1
23	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers	Recruiting	NCT03500627	Phase 1	OP-101
24	Human Placental-Derived Stem Cell Transplantation	Active, not recruiting	NCT01586455	Phase 1	Human Placental Derived Stem Cell
25	MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)	Withdrawn	NCT02410239	Phase 1
26	Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)	Withdrawn	NCT01787578	Phase 1	Sobetirome
27	Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children	Unknown status	NCT00278044	Not Applicable
28	Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Unknown status	NCT00005900
29	The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)	Completed	NCT01165060	Not Applicable	Bezafibrate
30	Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy	Completed	NCT01594853	Not Applicable
31	Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy	Completed	NCT00004450	Not Applicable	glyceryl trierucate;glyceryl trioleate;interferon beta;thalidomide
32	Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders	Completed	NCT01626092	Not Applicable	Campath-1H;Clofarabine;Melphalan;Cyclosporine A;Mycophenolate mofetil
33	Newborn Screening for Adrenoleukodystrophy	Recruiting	NCT02952482
34	A Study to Prospectively Assess Disease Progression in Male Children With X-ALD	Recruiting	NCT03278899
35	Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)	Recruiting	NCT02204904
36	Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants	Available	NCT01881334
37	Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product	Enrolling by invitation	NCT02698579
38	Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy	No longer available	NCT02233257		Lorenzo's Oil
39	Study of Bile Acids in Patients With Peroxisomal Disorders	Terminated	NCT00004442	Not Applicable	chenodeoxycholic acid;cholic acid;ursodiol
40	Early Diagnosis Of Childhood Cerebral ALD	Withdrawn	NCT02948062

Search NIH Clinical Center for Adrenomyeloneuropathy

Sources

Genetic Tests for Adrenomyeloneuropathy

Sources

Anatomical Context for Adrenomyeloneuropathy

MalaCards organs/tissues related to Adrenomyeloneuropathy:

⁴¹

Brain, Spinal Cord, Bone, Liver, T Cells, Bone Marrow, Skin

Sources

Publications for Adrenomyeloneuropathy

Articles related to Adrenomyeloneuropathy:

(show top 50) (show all 129)

#	Title	Authors	Year
1	Novel ABCD1 Gene Mutation in Adrenomyeloneuropathy with Hypoplasia and Agenesis of the Corpus Callosum. ( 29966135 )	Qiu Y....Hong D.	2018
2	A Novel Variant in <i>ABCD1</i> Gene Presenting as Adolescent-Onset Atypical Adrenomyeloneuropathy With Spastic Ataxia. ( 29740390 )	Chen Y....Wang K.	2018
3	Microglial dysfunction as a key pathological change in adrenomyeloneuropathy. ( 29059709 )	Gong Y....Eichler F.	2017
4	Highly asymmetric and subacutely progressive motor weakness with unilateral T2-weighted high intensities along the pyramidal tract in the brainstem in adrenomyeloneuropathy. ( 28991658 )	Tsuboi T....Katsuno M.	2017
5	Generation of two induced pluripotent stem cell (iPSC) lines from X-linked adrenoleukodystrophy (X-ALD) patients with adrenomyeloneuropathy (AMN). ( 29065337 )	Son D....You S.	2017
6	A first case of adrenomyeloneuropathy with mutation Y174S of the adrenoleukodystrophy gene. ( 28456143 )	Horikawa Y....Takeda J.	2017
7	Adrenomyeloneuropathy due to mutation in the ABCD1 gene as underlying factor in spastic paraparesis. ( 29243459 )	Ylikallio E....Tyynismaa H.	2017
8	MicroRNA Profiling Identifies miR-196a as Differentially Expressed in Childhood Adrenoleukodystrophy and Adult Adrenomyeloneuropathy. ( 26843114 )	Shah N....Singh I.	2016
9	Oligosymptomatic adrenomyeloneuropathy due to a novel mutation in the ABCD1 start codon. ( 27423567 )	Dunkl V....Lehmann H.C.	2016
10	Quantitative MRI of the spinal cord and brain in adrenomyeloneuropathy: in vivo assessment of structural changes. ( 27068048 )	Castellano A....Salsano E.	2016
11	Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy. ( 26370417 )	Ruiz M....Pujol A.	2015
12	Romiplostim mitigates dose-limiting thrombocytopenia of erucic acid for adrenomyeloneuropathy. ( 25854532 )	Shin D.S....Rosove M.H.	2015
13	Multiple endocrine disorders associated with adrenomyeloneuropathy and a novel mutation of the ABCD1 gene. ( 24685009 )	Triantafyllou P....Zafeiriou D.I.	2014
14	Abadie's sign in adrenomyeloneuropathy. ( 24726718 )	Ohtomo R....Iwata A.	2014
15	Clinical and genetic aspects in twelve Korean patients with adrenomyeloneuropathy. ( 24719134 )	Park H.J....Kim S.M.	2014
16	Yoga as Therapy for Neurodegenerative Disorders: A Case Report of Therapeutic Yoga for Adrenomyeloneuropathy. ( 26770098 )	Muhammad C.M....Moonaz S.H.	2014
17	Adrenomyeloneuropathy with bulbar palsy: A rare association. ( 25221415 )	Chafale V.A....Senapati A.K.	2014
18	Frequent occurrence of cerebral demyelination in adrenomyeloneuropathy. ( 25378668 )	de Beer M....van Geel B.M.	2014
19	Comment on the paper &quot;Effect of statin treatment on adrenomyeloneuropathy with cerebral inflammation: a revisit&quot;. ( 24018110 )	Engelen M....Kemp S.	2013
20	Adrenomyeloneuropathy presenting with adrenal insufficiency. ( 24020038 )	Park H.D....Kang J.H.	2013
21	Effect of statin treatment on adrenomyeloneuropathy with cerebral inflammation: a revisit. ( 22795299 )	Shih C.C....Chao C.Y.	2013
22	Reproductive function in men affected by X-linked adrenoleukodystrophy/adrenomyeloneuropathy. ( 22048970 )	Stradomska T.J....Tylki-Szymanska A.	2012
23	Adrenomyeloneuropathy. ( 23405547 )	Misra S....Vajresware .	2012
24	Strength: a relevant link to functional performance in the neurodegenerative disease of adrenomyeloneuropathy. ( 22544816 )	Keller J.L....Zackowski K.M.	2012
25	Intravenous immunoglobulin treatment in a patient with adrenomyeloneuropathy. ( 23009600 )	JA...Nielsen J.E.	2012
26	X-linked adrenomyeloneuropathy due to a novel missense mutation in the ABCD1 start codon presenting as demyelinating neuropathy. ( 22176151 )	Engelen M....de Visser M.	2011
27	Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible? ( 21399389 )	Cappa M....Di Biase A.	2011
28	Treatment of an adrenomyeloneuropathy patient with Lorenzo's oil and supplementation with docosahexaenoic acid--a case report. ( 21871076 )	Terre'Blanche G....Mienie L.J.	2011
29	Efferent and afferent evoked potentials in patients with adrenomyeloneuropathy. ( 19963315 )	Matsumoto H....Ugawa Y.	2010
30	Picture of the month: adrenoleukodystrophy and adrenomyeloneuropathy. ( 20048250 )	Burke S....Quintos J.B.	2010
31	Quantitative magnetization transfer characteristics of the human cervical spinal cord in vivo: application to adrenomyeloneuropathy. ( 19097204 )	Smith S.A....Stanisz G.J.	2009
32	Auditory function in adrenomyeloneuropathy. ( 18199457 )	Pillion J.P....Raymond G.V.	2008
33	Adrenomyeloneuropathy, presenting with sub-acute spastic paraparesis and Addison's disease. ( 21063355 )	Periasamy V....Khan R.A.	2008
34	Prominent brain axonal damage and functional reorganization in &quot;pure&quot; adrenomyeloneuropathy. ( 17875914 )	Marino S....De Stefano N.	2007
35	The neuropsychiatry of adrenomyeloneuropathy. ( 17805216 )	Walterfang M.A....Velakoulis D.	2007
36	A novel ABCD1 gene mutation in a Chinese-Taiwanese patient with adrenomyeloneuropathy. ( 17509471 )	Liu Y.T....Lin K.P.	2007
37	Sensorimotor function and axonal integrity in adrenomyeloneuropathy. ( 16401738 )	Zackowski K.M....Moser H.W.	2006
38	Transcranial magnetic stimulation after conditioning stimulation in two adrenomyeloneuropathy patients: delayed but facilitated motor-evoked potentials. ( 17049132 )	Lai K.L....Chen J.T.	2006
39	Adrenomyeloneuropathy in patients with 'Addison's disease': genetic case analysis. ( 16672758 )	Mukherjee S....Harvey J.N.	2006
40	Plasma levels of adrenomedullin in patients with adrenoleukodystrophy/adrenomyeloneuropathy. ( 15711093 )	Letizia C....Cappa M.	2005
41	Adrenomyeloneuropathy: report of a new mutation in a French Canadian female. ( 16018167 )	Dionne A....DuprAc N.	2005
42	Diffusion tensor-based imaging reveals occult abnormalities in adrenomyeloneuropathy. ( 16240348 )	Dubey P....Raymond G.V.	2005
43	Spinal cord atrophy in adrenomyeloneuropathy. ( 16009777 )	Israel H....Ploner C.J.	2005
44	Spectroscopic evidence of cerebral axonopathy in patients with &quot;pure&quot; adrenomyeloneuropathy. ( 15668429 )	Dubey P....Raymond G.V.	2005
45	Adrenomyeloneuropathy. ( 16121813 )	Mehndiratta M.M....Pandey S.	2005
46	Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone. ( 16362829 )	Wichers-Rother M....KAPhler W.	2005
47	Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy. ( 15911801 )	Fatemi A....Golay X.	2005
48	Adrenomyeloneuropathy as a cause of primary adrenal insufficiency and spastic paraparesis. ( 15505272 )	Spurek M....Khandwala H.M.	2004
49	Adrenomyeloneuropathy, a dynamic progressive disorder: brain magnetic resonance imaging of two cases. ( 15007575 )	Mo Y.H....Liu H.M.	2004
50	A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy. ( 12939429 )	Mundy H.R....Lee P.J.	2003

Sources

Genes for Adrenomyeloneuropathy

Genes related to Adrenomyeloneuropathy (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ABCD1	ATP Binding Cassette Subfamily D Member 1	Protein Coding	26.82	GeneCards inferred via : Disorders Publications (show sections)
2	AMACR	Alpha-Methylacyl-CoA Racemase	Protein Coding	17.68	GeneCards inferred via : Summaries (show sections)
3	CGA	Glycoprotein Hormones, Alpha Polypeptide	Protein Coding	16.83	GeneCards inferred via : Publications (show sections)
4	ADM	Adrenomedullin	Protein Coding	16.83	GeneCards inferred via : Publications (show sections)
5	SLC25A17	Solute Carrier Family 25 Member 17	Protein Coding	6.83	GeneCards inferred via : Publications (show sections)
6	MIR196A1	MicroRNA 196a-1	RNA Gene	6.83	GeneCards inferred via : Publications (show sections)

Sources

Variations for Adrenomyeloneuropathy

Sources

Expression for Adrenomyeloneuropathy

Search GEO for disease gene expression data for Adrenomyeloneuropathy.

Sources

Pathways for Adrenomyeloneuropathy

Pathways related to Adrenomyeloneuropathy according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	G alpha (s) signalling events ⁶⁶	11.32	ADM CGA
2	Peroxisome ³⁷	11.05	ABCD1 AMACR SLC25A17
3	Peroxisomal lipid metabolism ⁶⁶ Show member pathways Alpha-oxidation of phytanate ⁶⁶ Beta-oxidation of pristanoyl-CoA ⁶⁶ Beta-oxidation of very long chain fatty acids ⁶⁶ fatty acid alpha-oxidation ¹	10.52	ABCD1 AMACR SLC25A17

Sources

GO Terms for Adrenomyeloneuropathy

Cellular components related to Adrenomyeloneuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	peroxisomal membrane	GO:0005778	9.16	ABCD1 SLC25A17
2	integral component of peroxisomal membrane	GO:0005779	8.96	ABCD1 SLC25A17
3	peroxisome	GO:0005777	8.8	ABCD1 AMACR SLC25A17

Biological processes related to Adrenomyeloneuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	fatty acid beta-oxidation	GO:0006635	9.16	ABCD1 SLC25A17
2	developmental growth	GO:0048589	8.96	ADM CGA
3	fatty acid beta-oxidation using acyl-CoA oxidase	GO:0033540	8.62	ABCD1 AMACR

Molecular functions related to Adrenomyeloneuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	hormone activity	GO:0005179	8.62	ADM CGA

Sources

Sources for Adrenomyeloneuropathy

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia